AstraZeneca PLC is 139.4x more valuable than Harmony Biosciences Holdings, Inc. by market capitalization ($286.27 B vs $2.05 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | HRMY | AZN |
|---|---|---|
| Market cap | $2.05 B | $286.27 B |
| US-listed rank | #2085 | #45 |
| Revenue (latest FY) | $868.45M | - |
| Net income (latest FY) | $158.69M | - |
| Net margin | 18.3% | - |
| P/E (trailing FY) | 12.9 | - |
| SEC filings | 434 | 1,004 |
AstraZeneca PLC is 139.4x more valuable than Harmony Biosciences Holdings, Inc. by market capitalization ($286.27 B vs $2.05 B).
Full pages: Harmony Biosciences Holdings, Inc. and AstraZeneca PLC, or browse the full rankings.